{
  "guideline": {
    "id": "PA166265162",
    "name": "Annotation of DPWG Guideline for carbamazepine and HLA-B",
    "relatedChemicals": [
      {
        "id": "PA448785",
        "name": "carbamazepine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "source": "DPWG",
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451699220,
            "_label": "*15:02:01",
            "function": {
              "term": "Presence",
              "termId": "haplotypeTags:1445558333"
            }
          },
          {
            "id": 1451699280,
            "_label": "*15:11",
            "function": {
              "term": "Presence *15:11",
              "termId": "alleleFunction:1451699221"
            }
          },
          {
            "id": 1451698846,
            "_label": "Other",
            "function": {
              "term": "Absence",
              "termId": "haplotypeTags:1445558334"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA532",
            "name": "chr6",
            "symbol": null
          },
          "strand": "minus",
          "id": "PA35056",
          "name": "major histocompatibility complex, class I, B",
          "symbol": "HLA-B"
        }
      }
    ],
    "@id": "https://pharmgkb.org/guidelineAnnotation/PA166265162",
    "version": 3
  },
  "annotationGroups": [
    {
      "id": "PA166265402",
      "name": "*1511 present",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Possibly",
        "termId": "rxChange:1448602496"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Presence *15:11",
        "HLA-B:Presence *15:11/Presence *15:11"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451698843,
        "html": "<ul>\n<li>\n<p>Carefully weigh the risk of SJS/TEN against the benefits</p>\n</li>\n<li>\n<p>If an alternative is an option, choose an alternative</p>\n</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451698842,
        "html": "<p>Patients with this genetic variation have an increased risk of experiencing the life-threatening cutaneous adverse event Stevens-Johnson syndrome/toxic epidermal necrolysis\n(SJS/TEN). The risk of carbamazepine-induced SJS/TEN in patients with the HLA-B*1502 allele, which carries a 4.6-6.6 times higher risk than the HLA-B*1511 allele, is 1.8- 3.4%. This would equate to a risk of carbamazepine-induced SJS/TEN in these patients of 0.27-0.73%.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166265541",
      "name": "1511 and 1502",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "HLA-B:Presence/Presence *15:11"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451699321,
        "html": "<p>The guideline does not provide a recommendation for carbamazepine in patients with both HLA-B*15:02 and HLA-B*15:11 alleles or positive for both HLA-B*15:02 and HLA-B*15:11 tests.</p>\n"
      },
      "implications": {
        "id": 1451699320,
        "html": "<p>The guideline does not provide a description of the impact of the presence of both HLA-B*15:02 and HLA-B*15:11 alleles on carbamazepine.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166265401",
      "name": "*15:02 positive",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Possibly",
        "termId": "rxChange:1448602496"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Presence",
        "HLA-B:Presence/Presence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782581,
        "html": "<ul>\n<li>Choose an alternative if possible. Phenytoin, lamotrigine and oxcarbazepine also pose an increased risk of SJS/TEN in these patients, but the final risk is 10-fold lower for these medicines than for carbamazepine. Furthermore, in the case of oxcarbazepine, the most severe forms (SJS/TEN overlap and TEN) have not been observed.</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451782580,
        "html": "<p>Patients with this genetic variation have a severely increased risk of experiencing the life-threatening cutaneous adverse event Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The risk of carbamazepine-induced SJS/TEN in these patients is 1.8-3.4%.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166265403",
      "name": "*15:02 negative",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Absence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782583,
        "html": "<p>The guideline does not provide a recommendation for carbamazepine in patients with no HLA-B*15:02 alleles or negative for the.HLA-B*15:02 test.</p>\n"
      },
      "implications": null,
      "activityScore": {
        "id": 1451782582,
        "html": "<p>The guideline does not provide a description of the impact of the absence of HLA-B*15:02 alleles on carbamazepine.</p>\n"
      }
    }
  ],
  "citations": []
}